Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib in pediatric recurrent or refractory solid tumors
NCT02808650Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of prexasertib in solid tumor and central nervous system tumor, sponsored by Children's Oncology Group. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Feb 2017; status: completed.
02
Drugs
prexasertib
03
Conditions
solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT02808650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808650.